phase 1_completion
savePolfa Tarchomin SA — empagliflozin (Phase I Trial Completion)
community read0 votes
Therapy area: Cardiovascular, Metabolic Disorders. Indication: Congestive Heart Failure (Heart Failure), Type 2 Diabetes
Data sources
globaldata
Found something off?
drug timeline · 8
- approvalSYNJARDY (EMPAGLIFLOZIN) — FDA approvalOct 24, 2025 · 353d ago
- approvalJARDIANCE (EMPAGLIFLOZIN) — FDA approvalOct 24, 2025 · 353d ago
- approvalSYNJARDY (EMPAGLIFLOZIN) — FDA approvalMar 7, 2025 · 584d ago
- approvalSYNJARDY (EMPAGLIFLOZIN) — FDA approvalOct 30, 2023 · 1078d ago
- approvalJARDIANCE (EMPAGLIFLOZIN) — FDA approvalSep 21, 2023 · 1117d ago
- approvalJARDIANCE (EMPAGLIFLOZIN) — FDA approvalSep 12, 2023 · 1126d ago
- approvalJARDIANCE (EMPAGLIFLOZIN) — FDA approvalJun 20, 2023 · 1210d ago
- approvalSYNJARDY (EMPAGLIFLOZIN) — FDA approvalJun 20, 2023 · 1210d ago
🐶 often sniffed alongside
top 6- tagApproval70 co-mentions · 35 sources
- drugTRIJARDY XR35 co-mentions · 35 sources
- companyBoehringer Ingelheim Corp35 co-mentions · 35 sources
- tagSmall Molecule35 co-mentions · 35 sources
- drugSYNJARDY XR15 co-mentions · 15 sources
- drug(empagliflozin + metformin hydrochloride ER)15 co-mentions · 15 sources
comments(0)
5-min edit window · permanent after that